TG Therapeutics, Inc. (NASDAQ:TGTX) CFO Sean A. Power Sells 10,021 Shares

TG Therapeutics, Inc. (NASDAQ:TGTX) CFO Sean A. Power sold 10,021 shares of TG Therapeutics stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $28.53, for a total value of $285,899.13. Following the transaction, the chief financial officer now owns 660,611 shares of the company’s stock, valued at $18,847,231.83. The trade was a 1.49 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

TG Therapeutics Price Performance

TGTX remained flat at $28.00 during trading hours on Tuesday. The company had a trading volume of 2,930,795 shares, compared to its average volume of 2,870,394. TG Therapeutics, Inc. has a 12-month low of $12.84 and a 12-month high of $36.84. The business has a fifty day moving average of $31.26 and a 200-day moving average of $25.16. The stock has a market cap of $4.36 billion, a PE ratio of -279.97 and a beta of 2.24. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). The company had revenue of $83.90 million during the quarter, compared to analysts’ expectations of $81.68 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. TG Therapeutics’s revenue was down 49.4% on a year-over-year basis. During the same period last year, the firm posted $0.73 earnings per share. Analysts expect that TG Therapeutics, Inc. will post 0.17 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on TGTX shares. TD Cowen started coverage on shares of TG Therapeutics in a report on Tuesday, October 29th. They set a “buy” rating and a $50.00 price target on the stock. JPMorgan Chase & Co. raised their target price on TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a research report on Monday, November 25th. StockNews.com cut TG Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, December 22nd. The Goldman Sachs Group raised their price objective on TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Finally, HC Wainwright upped their price target on shares of TG Therapeutics from $49.00 to $55.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $40.67.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. State Street Corp lifted its position in shares of TG Therapeutics by 35.8% during the third quarter. State Street Corp now owns 9,094,158 shares of the biopharmaceutical company’s stock worth $212,712,000 after purchasing an additional 2,398,015 shares in the last quarter. Marshall Wace LLP acquired a new stake in TG Therapeutics during the 2nd quarter worth approximately $36,501,000. Hood River Capital Management LLC boosted its position in TG Therapeutics by 6.7% in the 2nd quarter. Hood River Capital Management LLC now owns 1,572,929 shares of the biopharmaceutical company’s stock valued at $27,982,000 after buying an additional 98,892 shares during the period. Charles Schwab Investment Management Inc. grew its stake in shares of TG Therapeutics by 0.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,184,609 shares of the biopharmaceutical company’s stock worth $27,708,000 after acquiring an additional 7,939 shares in the last quarter. Finally, Principal Financial Group Inc. raised its stake in shares of TG Therapeutics by 1,549.4% in the third quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company’s stock valued at $18,061,000 after acquiring an additional 725,371 shares in the last quarter. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.